Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

Inclusion Criteria: Patients can be included if all of the following criteria are met: * Diagnosis of COPD * Symptomatic (with regard to dyspnea (mMRC Dyspnea score ≥1) AND with regard to symptoms (CAT Score ≥10) at the same time) * Patients on LABA/ICS maintenance therapy who are switched to Spiolto® Respimat® in the new reusable inhaler or a free/fixed triple combination of LABA + LAMA + ICS at Visit 1 at the discretion of the treating physician. * Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel * Male or female * Patients aged ≥40 years of age * Written informed consent prior to study participation * The patient is willing and able to follow the procedures outlined in the protocol Exclusion Criteria: * Patients with contraindications acc. to SmPC * Patients not on LABA/ICS maintenance treatment at visit 1, e.g., mono or dual bronchodilation only, ICS only, or a triple combination of LAMA + LABA + ICS (either as a fixed combination product or as separate components) * Lack of informed consent * Pregnant and/or lactating females * Acute exacerbation of COPD (within 4 weeks prior to Visit 1) * Frequently exacerbating patients, i. e. patients with ≥2 moderate exacerbations within the last 12 months or ≥1 exacerbation leading to hospitalization within the last 12 months * Acute respiratory failure (pH \<7,35 and/ or respiratory rate \>30/min within 3 months prior to Visit 1) * History or current diagnos…